EORTC-1333-GUCG/PEACE III trial endpoint reached

Friday 12 July, Brussels, Belgium: EORTC is pleased to announce that the primary endpoint has been reached in the EORTC-1333-GUCG/PEACE III Trial.

The phase III EORTC-1333-GUCG/PEACE III trial is a randomised multicentre phase III trial comparing enzalutamide vs. a combination of radium-223 dichloride and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

The full results will be presented at an upcoming medical meeting.

We extend our gratitude to the patients, investigators, and research teams who participated in the EORTC-1333-GUCG/PEACE III Trial and made this achievement possible.

This trial is supported by an investigator driven clinical trial agreement from Bayer HealthCare Pharmaceuticals Inc. and Astellas Pharma Europe. This trial is a collaboration between EORTC, UNICANCER, Clinical Trial Ireland (CTI), Canadian Urological Oncology Group (CUOG) and Latin American Cooperative Oncology Group (LACOG).

https://clinicaltrials.gov/study/NCT02194842

On the 14th of May, 2024 the Italian central Ethics Committee, the Comitato Etico Area Vasta Emilia Nord (AVEN), granted EORTC approval for reconsenting patients for the use of the PEACE III data by the Bayer Healthcare for regulatory and marketing purposes. For the full statement please click here.

ENDS